(Q40026216)

English

Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis

scientific article published on September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 September 2017

Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis (English)

1 reference

Europe PubMed Central

16 September 2017

cervix uterine cancer

1 reference

based on heuristic

inferred from title

Eduardo L. Franco

9

1 reference

Europe PubMed Central

16 September 2017

Chris J L M Meijer

4

object named as

Chris J L M Meijer

1 reference

Europe PubMed Central

16 September 2017

author name string

Raina M Rogoza

1

1 reference

Europe PubMed Central

16 September 2017

Nicole Ferko

2

1 reference

Europe PubMed Central

16 September 2017

James Bentley

3

1 reference

Europe PubMed Central

16 September 2017

Johannes Berkhof

5

1 reference

Europe PubMed Central

16 September 2017

Kung-Liahng Wang

6

1 reference

Europe PubMed Central

16 September 2017

Levi Downs

7

1 reference

Europe PubMed Central

16 September 2017

Jennifer S Smith

8

1 reference

Europe PubMed Central

16 September 2017

language of work or name

0 references

publication date

1 September 2008

1 reference

Europe PubMed Central

16 September 2017

1 reference

Europe PubMed Central

16 September 2017

26 Suppl 5

1 reference

Europe PubMed Central

16 September 2017

F46-58

1 reference

Europe PubMed Central

16 September 2017

Chapter 7: Achievements and limitations of cervical cytology screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Chapter 19: Cost-effectiveness of cervical cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Chapter 2: The burden of HPV-related cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Cervical cancer screening following prophylactic human papillomavirus vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

The Bethesda System for reporting cervical/vaginal cytologic diagnoses: report of the 1991 Bethesda workshop. The Bethesda System Editorial Committee

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Evolution of the health economics of cervical cancer vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Willingness to pay for a quality-adjusted life year: in search of a standard

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Systematic overview of cost-utility assessments in oncology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Model for assessing human papillomavirus vaccination strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Evaluating human papillomavirus vaccination programs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Cost-effectiveness of a potential vaccine for human papillomavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Commentary: Health inequity could increase in poor countries if universal HPV vaccination is not adopted

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Chapter 10: New dimensions in cervical cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Natural history of cervicovaginal papillomavirus infection in young women.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Natural history of cervical squamous intraepithelial lesions: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Natural history of dysplasia of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of The Netherlands, 1986-1996

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Estimates of cancer incidence and mortality in Europe in 1995

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Distribution of 14 high risk HPV types in cervical intraepithelial neoplasia detected by a non-radioactive general primer PCR mediated enzyme immunoassay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995-2001

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Cervical cancer screening in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

The frequency of Pap smear screening in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Human papillomavirus testing in primary cervical screening.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Colposcopy for the diagnosis of squamous intraepithelial lesions: A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

The management of cervical intra-epithelial neoplasia (CIN): extensiveness and costs in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Human papillomavirus testing for triage of women referred because of abnormal smears. a decision analysis considering outcomes and costs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Stage-specific treatment costs for cervical cancer in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.039

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.02.039

1 reference

Europe PubMed Central

16 September 2017

1 reference

Europe PubMed Central

16 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40026216&oldid=2043826134"